PEPG Investors Have Opportunity To Join PepGen Inc Securities Fraud Investigation With The Schall Law FirmAccesswire • 08/06/24
Did PepGen Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - PEPGAccesswire • 08/06/24
Did PepGen Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- PEPGAccesswire • 08/05/24
ATTENTION PEPG SHAREHOLDERS: Investors who Lost Money on PepGen Inc. are Urged to Contact Levi & Korsinsky About an Ongoing InvestigationAccesswire • 08/04/24
PepGen Inc. (PEPG) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their RightsAccesswire • 08/02/24
Down -39.63% in 4 Weeks, Here's Why You Should You Buy the Dip in PepGen (PEPG)Zacks Investment Research • 08/02/24
PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current TreatmentsSeeking Alpha • 07/31/24
PEPG Investors Have Opportunity to Join PepGen Inc. Securities Fraud Investigation with the Schall Law FirmBusiness Wire • 07/31/24
PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular DystrophyBusiness Wire • 07/30/24
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate CommunicationsBusiness Wire • 07/02/24
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/14/24
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 03/13/24
Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 03/12/24
PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 03/11/24
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 03/06/24
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 03/04/24
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1GlobeNewsWire • 02/20/24
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common StockGlobeNewsWire • 02/07/24